Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy

Br J Haematol. 2019 Aug;186(3):e31-e35. doi: 10.1111/bjh.15861. Epub 2019 Mar 11.

Authors

Adam J Olszewski^{1

2}, Anna D Chorzalska^{1

2

3}, Annette S Kim⁴, Peter J Quesenberry^{1

2}, Mary L Lopresti^{1

2}, Mary A Fenton^{1

2}, John L Reagan^{1

2}, James N Butera^{1

2}, Ilyas Sahin^{1

2}, Celine Hamel², Jordan Robison², Max Petersen^{1

3}, Patrycja M Dubielecka^{1

2

3}

Affiliations

¹ The Warren Alpert Medical School of Brown University, Providence, RI, USA.
² Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA.
³ Signal Transduction Lab, Rhode Island Hospital, Providence, RI, USA.
⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

No abstract available

Keywords: chemotherapy; clonal haematopoiesis; lymphoma; next-generation sequencing; treatment-related myeloid neoplasm.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Cancer Survivors
Clonal Evolution
Female
Hematopoiesis / physiology*
Humans
Male
Middle Aged
Neoplasms / blood*
Neoplasms / drug therapy
Neoplasms / genetics
Neoplasms / mortality

Grants and funding